GW 583340 dihydrochloride
Cat. No. 2239
Chemical Name: N-[3-Chloro-4-[(3-fluorophenyl)meth
Biological ActivityPotent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC50 values are 0.01 and 0.014 μM respectively). Selectively inhibits growth of human tumor cells overexpressing EGFR and ErbB2 (IC50 values are 0.11 μM for inhibition of HN5, N87 and BT474 tumor cell lines vs. > 30 μM for inhibition of non-tumor cell line HFF). Inhibits tumor growth in vivo by ~ 80% in a murine xenograft model following oral administration.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Gaul et al (2003) Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines. Bioorg.Med.Chem.Lett. 13 637. PMID: 12639547.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GW 583340 dihydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: GW 583340 dihydrochloride, supplier, Potent, dual, EGFR, ErbB2, inhibitors, orally, active, Epidermal, Growth, Factors, Receptors, Her, Receptor, Tyrosine, Kinases, RTKs, GW583340, dihydrochloride, GlaxoSmithKline, GSK, Tocris Bioscience, EGFR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective ErbB2 inhibitorMitoglitazone
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitorCHMFL-FLT3-122
Potent and selective FLT3 inhibitorGW 2580
Selective cFMS kinase inhibitor; orally bioavailable
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.